Clinical trial
A european phase III, multicentre, double-blind, randomised, monotherapy, 12-month study of Milnacipran for the treatment of the Fibromyalgia Syndrome
To assess the long-term safety of milnacipran used for the treatment of FMS at doses of 100, 150 and 200 mg daily.
| Category | Value |
|---|---|
| Study start date | 2006-10-31 |